Raltegravir

An accurate, precise and reproducible RP-HPLC method for the simultaneous determination of Lamivudine and Raltegravir in the bulk API dosage form has been developed and validated. Chromatographic separation was carried out on Agilent C18 (100×4.6mm, 3.5u particle size) column using mobile phase composed of phosphate buffer (PH3.0): acetonitrile (ACN) in ratio 60:40 at a flow rate of 0.8ml/min. The analyte was monitored using DAD detector at 231nm. The retention times were found to be 1.12 and 4.08 for Lamivudine and Raltegravir respectively. The linearity for each were found in the range 10-60µg/ml and their regression values are 0.998 and 0.999 respectively. The developed method was validated as per ICH guidelines.

This paper describes a simple, rapid and sensitive bioanalytical method based on liquid chromatography / tandem mass spectrometry (LC–MS/MS) for the determination of integrase inhibitor raltegravir in human plasma samples. Carbamazepine was used as an internal standard (IS). Analyte and the internal standard were extracted from 200 µL of human plasma via solid phase extraction. The chromatographic separation was achieved on a C18 column by using a mixture of acetonitrile and 0.1% formic acid (90:10, v/v) as the mobile phase at a flow rate of 0.8 mL/min. The calibration curve obtained was linear (r2 ³ 0.99) over the concentration range of 20.1–4007 ng/mL. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. A run time of 2.0 min for each sample made it possible to analyze more number of samples in short time, thus increasing the productivity. The proposed method was found to be applicable to pharmacokinetic studies in humans.